STRIVE: CD101 Compared to Caspofungin Followed by Oral Step Down Treatment in Subjects With Candidemia

STRIVE: Phase 2 Multicenter, Randomized, Double-blind Trial of CD101 Injection Versus Caspofungin Followed by Optional Oral Fluconazole Step-down in Subjects with Candidemia.

 

Condition Intervention Phase
Candidemia
Mycoses
Fungal Infection
Fungemia
Drug: CD101 Injection
Drug: Caspofungin
Drug: Fluconazole
Drug: intravenous placebo
Drug: oral placebo
Phase 2

 

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: STRIVE: A Phase 2, Multicenter, Randomized, Double-blind Trial of the Safety, Tolerability, and Efficacy of CD101 Injection vs Intravenous Caspofungin Followed By Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia

Antifungal name: 

Date of article/Start date of trial: 

Wednesday, March 16, 2016

Trial phase: 

Phase 2

ClinicalTrials.gov ID: 

NCT02734862

Trial status: 

Active
New antifungal drugs